Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2012

View Archived Issues

Lundbeck reports on second quarter of 2012

Additional causes of startle disease identified / News in Context

Combination regimen shows efficacy in patients with tuberculosis

Astellas Pharma announces highlights for second quarter of 2012

Mitsubishi Tanabe Pharma reviews second quarter 2012

Multiple new global ALS research grants issued

Amylin satisfies financial obligations to Lilly for exenatide

Marqibo receives accelerated approval

Sosei transfers SD-118 rights

Phase III AVAglio trial meets coprimary endpoint

Pirfenidone approved in South Korea

Novel pim kinase inhibitors synthesized in Spain

Research in Malaysia yields new curcumin derivatives

Novel GPR119 agonists disclosed by Boehringer Ingelheim Pharma

Convergence Pharmaceuticals reports novel candidate analgesics

Scientists in Italy and U.S. jointly develop new 3-HAO inhibitors

German team designs new candidate drugs for cardiovascular diseases

Recombinant hypoallergenic combination vaccines developed for house dust mite allergy

Intercept Pharmaceuticals secures funds for development of its lead product

Data presented on temsirolimus combination regimen in kidney cancer

FDA places clinical hold on anthrax vaccine program

Elan announces planned spin-off

FDA approves first drug for diabetic macular edema

Pluristem Therapeutics reports on PLX-PAD trial

Phase III study of OCV-C01 advances

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...